Verrica Pharmaceuticals inc (VRCA) reported a Q4 2025 adjusted loss of $0.51 per share. Top-line revenue was $5.1M. The dermatology therapeutics company develops and sells medications for the treatment of skin diseases in the United States.
Verrica’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts. The company has also completed phase II clinical trials for treating external genital warts and molluscum contagiosum.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.